GLP-1 Receptor Agonists and Male Hypogonadism: Leydig Cell GLP-1R, HPG Axis Decompression, and SHBG Dynamics

Visceral adipose tissue is metabolically distinct from subcutaneous fat in its high expression of CYP19A1 (aromatase), the enzyme responsible for peripheral testosterone-to-estradiol (T→E2) conversion. In men with functional hypogonadism, excess VAT drives a feedforward cycle: elevated E2 suppresses pituitary LH secretion via negative feedback, reducing testicular testosterone synthesis, which in turn reduces the androgenic inhibition of adipogenesis — facilitating further VAT accumulation.

GLP-1 receptor agonists preferentially reduce VAT relative to subcutaneous adipose tissue. The mechanism involves GLP-1R activation in adipocytes promoting lipolysis and reducing lipid storage, with VAT showing greater GLP-1R density and higher sensitivity to this effect. The clinical consequence is disproportionate VAT reduction — and therefore disproportionate reduction in CYP19A1 activity — relative to total weight lost.

The downstream effect on E2/T ratio is measurable within 8-12 weeks of initiating GLP-1RA therapy. Reduced E2 removes the suppressive signal on hypothalamic GnRH pulsatility and pituitary LH secretion, enabling endogenous testosterone synthesis to recover. This VAT-CYP19A1-E2-HPG feedback restoration is distinct from the direct HPG effects described below and operates additively with them.

Chronic hyperinsulinemia and insulin resistance suppress hypothalamic GnRH pulsatility through multiple mechanisms: direct inhibition of GnRH neurons via insulin receptor signaling in the arcuate nucleus, elevated inflammatory cytokines (TNF-α, IL-6) impairing hypothalamic function, and hyperinsulinemia-driven hepatic SHBG suppression altering androgen bioavailability. The net effect is functional suppression of the HPG axis without structural pituitary or gonadal pathology — the defining feature of functional hypogonadism.

GLP-1RAs improve insulin sensitivity through both central (reduced appetite → caloric restriction) and peripheral mechanisms (enhanced glucose-dependent insulin secretion, improved hepatic glucose metabolism, GLP-1R-mediated effects on skeletal muscle glucose uptake). Insulin sensitivity improvements frequently precede significant weight loss, consistent with clinical observations of early symptomatic improvement in libido and energy on GLP-1RAs before meaningful anthropometric change.

As insulin resistance normalizes, GnRH pulsatility recovers — restoring the amplitude and frequency of LH pulses that drive testicular testosterone synthesis. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) both rise in response, and downstream testosterone production follows. This HPG decompression pathway explains why testosterone gains on GLP-1RAs exceed what would be predicted from weight loss alone.

Leydig cells — the primary testosterone-producing cells in the testis — express functional GLP-1 receptors (GLP-1R). This discovery introduced a third, weight-independent mechanism for GLP-1RA-mediated testosterone recovery. GLP-1R activation in Leydig cells increases the transcription of steroidogenic acute regulatory protein (StAR), which mediates the rate-limiting step in testosterone biosynthesis: translocation of cholesterol from the outer to the inner mitochondrial membrane.

StAR upregulation directly increases substrate availability for the cytochrome P450 side-chain cleavage enzyme (CYP11A1), which converts cholesterol to pregnenolone — the committed step in steroidogenesis. This translates to increased testosterone output per Leydig cell, independent of LH stimulation amplitude. In rodent models, direct GLP-1R agonist infusion into the testicular environment increases testosterone production measurably within hours, demonstrating the gonadal GLP-1R pathway is pharmacologically accessible.

The clinical implication is that total testosterone gains on GLP-1RAs reflect at least three simultaneous mechanisms: reduced CYP19A1 catabolism, HPG axis signal recovery, and enhanced Leydig cell steroidogenic capacity. This mechanistic redundancy likely accounts for why GLP-1RAs outperform isocaloric diet and lifestyle interventions on testosterone recovery — identical weight loss through dietary restriction does not activate the Leydig cell GLP-1R pathway.

GLP-1 receptor agonist therapy increases hepatic sex hormone-binding globulin (SHBG) production, averaging +12 nmol/L in clinical studies. This SHBG elevation is mechanistically distinct from the testosterone-increasing pathways and partially offsets the gains in total testosterone. Because only free testosterone (the non-SHBG-bound fraction, approximately 2-3% of total) is bioavailable to androgen receptors, the clinical significance of total testosterone gains must be interpreted against concurrent SHBG changes.

In the 2025 Journal of Urology retrospective (n=411, baseline TT 247 ng/dL, BMI 34), mean total testosterone at 12 months was 421 ng/dL with 71% normalization rate. However, mean SHBG increase was also quantified, and calculated free testosterone showed a smaller but still clinically meaningful gain. This creates an important lab interpretation caveat: men on GLP-1RAs should request calculated free testosterone (using the Vermeulen formula from TT, SHBG, and albumin) rather than relying solely on total testosterone to assess androgen status.

Mineral interventions that modestly reduce SHBG — zinc (30mg bisglycinate) and magnesium glycinate (400mg) — may preserve more of the total testosterone gain as bioavailable free testosterone. If circadian rhythm normalization also occurs (GLP-1-mediated sleep improvement reducing apnea and improving sleep architecture), the testosterone circadian peak (7-9am) is better preserved, further improving the clinical picture beyond the laboratory values.